A Prospective Multi-centre, Non-interventional, observational Post Marketing Surveillance (PMS) Study of AdaliRelTM (Adalimumab) to Evaluate long-term safety in Patients With Active Rheumatoid arthritis in Routine Clinical Practice

Reliance Life Sciences Pv Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Diagnosis of Rheumatoid Arthritis according to the criteria based on American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria for Rheumatoid Arthritis according to routine clinical practice

•1.Pregnant women, nursing mothers or a planned pregnancy within 18 months of selection.Allergy to any of the excipients of adalimumab.Active TB. Also excluded are patients who have evidence of latent TB [evidence of tuberculosis based on standard hospital practice of TB screening]. Also excluded are patients with opportunistic infections including, but not limited to, evidence of active cytomegalovirus, active pneumocystis carinii, aspergillosis, or atypical mycobacterial infection, etc., within the previous 6 months.Patients with warnings / contraindications to AdaliRelÂ® (see warnings in full prescribing information in Appendix )

发起方

Reliance Life Sciences Pv Ltd